🇺🇸 FDA
Pipeline program

ISATUXIMAB

APHP210369

Phase 2 small_molecule active

Quick answer

ISATUXIMAB for Isatuximab in type I cryoglobulinaemia: A prospective pilot study is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Isatuximab in type I cryoglobulinaemia: A prospective pilot study
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials